Literature DB >> 3694593

Cytotoxic activity and phenotypic analysis of natural killer cells in early normal human pregnancy.

H Lee1, C D Gregory, G B Rees, I V Scott, P R Golding.   

Abstract

Peripheral blood lymphocytes taken from healthy women planning a pregnancy and then at various intervals up to the 16th week of pregnancy were assayed for natural killer (NK) cell activity against K562 target cells both in a 51Cr-release assay and in a single cell cytotoxicity assay. Results indicated a depression in NK activity from the earliest stages of pregnancy. The target binding capacity of the effector cells remained unimpaired up to 16 weeks, but a significant reduction in the post-binding lytic potential was observed, which parallelled the drop in cytotoxicity as assayed by the 51Cr-release method. The ability of individual effector cells to recycle and kill multiple targets remained essentially unimpaired. Analysis of lymphocyte subpopulations using the monoclonal antibodies anti-Leu-7 and anti-Leu-11b, which recognize NK cell-associated antigens, showed a significant reduction in the proportion of the mature, lytically active Leu-7-11+ cells capable of both binding and lysing K562 target cells. The suggestion that the depression in cytotoxicity may be associated with the reduction in the Leu-7-11+ subpopulation is supported by the high correlation levels observed between the proportion of Leu-7-11+ cells and target cell lysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3694593     DOI: 10.1016/0165-0378(87)90079-9

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  2 in total

1.  Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow cytometric analysis of peripheral blood mononuclear cells.

Authors:  G P Sacks; C W G Redman; I L Sargent
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

Review 2.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.